161 related articles for article (PubMed ID: 35034868)
1. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.
Caimi PF; Ardeshna KM; Reid E; Ai W; Lunning M; Zain J; Solh M; Kahl BS; Hamadani M
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e335-e339. PubMed ID: 35034868
[TBL] [Abstract][Full Text] [Related]
2. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
3. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
4. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Ahmed N; Hamadani M
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
[TBL] [Abstract][Full Text] [Related]
5. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Davis JA; Shockley A; Glode AE
J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
[No Abstract] [Full Text] [Related]
6. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
12. In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
Caimi PF; Hamadani M; Carlo-Stella C; Nickaeen M; Jordie E; Utsey K; Knab T; Zammarchi F; Cucchi D; Pantano S; Havenith K; Wang Y; Boni J
EJHaem; 2024 Feb; 5(1):76-83. PubMed ID: 38406517
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
Sermer D; Elavalakanar P; Abramson JS; Palomba ML; Salles G; Arnason J
Blood Rev; 2023 Jan; 57():101002. PubMed ID: 35989138
[TBL] [Abstract][Full Text] [Related]
14. Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
Dodero A; Bramanti S; Di Trani M; Pennisi M; Ljevar S; Chiappella A; Massimo M; Guidetti A; Corrado F; Nierychlewska PM; Di Rocco A; Lorenzini D; Daoud R; De Philippis C; Santoro A; Carlo-Stella C; Corradini P
Br J Haematol; 2024 Jan; 204(1):151-159. PubMed ID: 37690811
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
16. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
de Ramon Ortiz C; Wang S; Stathis A; Bertoni F; Zenz T; Novak U; Simonetta F
Hematol Oncol; 2024 Jan; 42(1):e3237. PubMed ID: 37937474
[TBL] [Abstract][Full Text] [Related]
17. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
Baek GT; Huang IJ; Gopal AK
Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
[TBL] [Abstract][Full Text] [Related]
18. New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Moore DC; Peery MR; Tobon KA; Raheem F; Hwang GS; Alhennawi L; Hughes ME
J Oncol Pharm Pract; 2022 Dec; 28(8):1848-1858. PubMed ID: 35469489
[TBL] [Abstract][Full Text] [Related]
19. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF; Ai WZ; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Wang Y; Qin Y; Wang L; Xu ZC; Carlo-Stella C
Haematologica; 2024 Apr; 109(4):1184-1193. PubMed ID: 37646659
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]